Pfizer Inc. today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback